Tirzepatide's GIP receptor activation adds a second hormone pathway that enhances satiety and energy expenditure beyond what GLP-1 alone provides
10.1016/s1570-0232(02)00618-9 J Chromatogr B Analyt Technol Biomed Life Sci
At Midi Health, we focus on the "clinical biohacks": evidence-based interventions like hormone therapy when appropriate, DEXA scans for bone health, and advanced lipid panels
Contact your healthcare provider if you experience: Bruises larger than two inches in diameter or that continue expanding after 24 hours Severe pain at the injection site that interferes with daily activities or doesn't improve within 48 hours Signs of infection including increasing warmth, redness spreading beyond the immediate injection site, purulent drainage, or fever above 100.4F (38C) Bruising that persists beyond three weeks without improvement Development of a hard lump or nodule beneath the skin that doesn't resolve Sudden increase in bruising frequency or severity compared to your usual pattern Bruising accompanied by unusual bleeding from other sites (gums, nose, or in urine/stool) Patients taking anticoagulant medications require particular vigilance
Some ignore temperature rise
On April 1, 2026, the FDA approved Eli Lillys FOUNDAYO (orforglipron) , the second oral GLP-1 approved for obesity, and arguably the one with the more patient-friendly convenience profile
